Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $2.19 billion. The enterprise value is $1.50 billion.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
Earnings Date | May 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
XENE has 76.73 million shares outstanding. The number of shares has increased by 11.90% in one year.
Current Share Class | 76.73M |
Shares Outstanding | 76.73M |
Shares Change (YoY) | +11.90% |
Shares Change (QoQ) | +0.38% |
Owned by Insiders (%) | 0.14% |
Owned by Institutions (%) | 94.09% |
Float | 70.88M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 296.93 |
Forward PS | n/a |
PB Ratio | 3.10 |
P/TBV Ratio | 3.11 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 200.49 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.66, with a Debt / Equity ratio of 0.01.
Current Ratio | 17.66 |
Quick Ratio | 17.43 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.60% and return on invested capital (ROIC) is -22.74%.
Return on Equity (ROE) | -31.60% |
Return on Assets (ROA) | -22.03% |
Return on Invested Capital (ROIC) | -22.74% |
Return on Capital Employed (ROCE) | -41.19% |
Revenue Per Employee | $22,936 |
Profits Per Employee | -$768,948 |
Employee Count | 327 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | -4.07M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.75% in the last 52 weeks. The beta is 1.22, so XENE's price volatility has been higher than the market average.
Beta (5Y) | 1.22 |
52-Week Price Change | -25.75% |
50-Day Moving Average | 33.58 |
200-Day Moving Average | 38.38 |
Relative Strength Index (RSI) | 31.64 |
Average Volume (20 Days) | 1,363,200 |
Short Selling Information
The latest short interest is 3.47 million, so 4.52% of the outstanding shares have been sold short.
Short Interest | 3.47M |
Short Previous Month | 3.58M |
Short % of Shares Out | 4.52% |
Short % of Float | 4.90% |
Short Ratio (days to cover) | 3.78 |
Income Statement
In the last 12 months, XENE had revenue of $7.50 million and -$251.45 million in losses. Loss per share was -$3.22.
Revenue | 7.50M |
Gross Profit | -219.84M |
Operating Income | -293.00M |
Pretax Income | -199.34M |
Net Income | -251.45M |
EBITDA | -290.36M |
EBIT | -293.00M |
Loss Per Share | -$3.22 |
Full Income Statement Balance Sheet
The company has $549.63 million in cash and $8.68 million in debt, giving a net cash position of $682.45 million or $8.89 per share.
Cash & Cash Equivalents | 549.63M |
Total Debt | 8.68M |
Net Cash | 682.45M |
Net Cash Per Share | $8.89 |
Equity (Book Value) | 703.96M |
Book Value Per Share | 9.19 |
Working Capital | 533.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$196.85 million and capital expenditures -$2.93 million, giving a free cash flow of -$199.78 million.
Operating Cash Flow | -196.85M |
Capital Expenditures | -2.93M |
Free Cash Flow | -199.78M |
FCF Per Share | -$2.60 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -3,906.60% |
Pretax Margin | -3,406.93% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.90% |
Shareholder Yield | -11.90% |
Earnings Yield | -11.50% |
FCF Yield | -9.14% |
Dividend Details Analyst Forecast
The average price target for XENE is $54.82, which is 92.42% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $54.82 |
Price Target Difference | 92.42% |
Analyst Consensus | Strong Buy |
Analyst Count | 11 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 43.97 and a Piotroski F-Score of 1.
Altman Z-Score | 43.97 |
Piotroski F-Score | 1 |